- Under Carlyle, VLCC has been opening up more and more slimming retail chains known for their various weight loss procedures
- The PE firm has no intention to stop, even after pharma companies have announced entry of GLP-1 medications like Mounjaro and Wegovy in India
- Though GLP-1 drugs have bankrupted Weight Watchers in the US, Carlyle isn’t fazed—instead pumping in more money into its weight-loss clinics
- Between weight loss regimes or GLP-1 drugs, Carlyle’s bet on VLCC is a win-win
Enter your email address to receive a daily summary of all our stories.
As Shreya climbed onto the weighing scale, a wave of anxiety rocked her, as it always did in such moments. A tiny reckoning in the works. The 27-year-old copywriter had even skipped lunch in preparation for this consultation, and her stomach grumbled in defiance.
After taking her height and weight measurements, the VLCC wellness counselor did a body-composition analysis and announced her verdict: Shreya could get leaner by reducing fat and acquiring more muscle mass.
Visual Stories
She was presented with three options: laser trimming sessions,
“After the consultation, I thought Ozempic will be cheaper and reduce my weight faster. But then I also read that patients end up gaining that lost weight back.
Share this article with your network
Send the article link to friends or colleagues who might find this story interesting or insightful.
Send the article link to friends or colleagues who might find this story interesting or insightful.